title: Effect of oral antihistamine premedication on mivacurium-induced histamine release and side effects.
abstract: In this randomized, double-blind, placebo-controlled study, we have examined histamine release, haemodynamic and cutaneous effects of mivacurium administered in low (0.105 mg kg-1 = 1.5 x ED95) and high (0.21 mg kg-1 = 3 x ED95) doses and assessed if oral pretreatment with H1/H2 antagonists would blunt the effects of mivacurium-induced histamine release. Patients received either ranitidine 300 mg and dimethindene 0.1 mg kg-1 (H1 blocker) or placebo, orally 1 h before induction of anaesthesia. Twelve patients were allocated to each group. Although plasma concentrations of histamine increased significantly in three patients in the placebo group given low-dose mivacurium, the mean value for the group was unchanged. Plasma concentrations of histamine increased significantly in five patients in the placebo group after high-dose mivacurium and the mean value was increased. There was no consistent correlation between haemodynamic changes, cutaneous manifestations and histamine concentrations. Significant cardiovascular reactions occurred in six patients in the placebo groups and in only one patient treated with antihistamines.
authors.affiliation: Institute of Anaesthesiology, Ludwig Maximilians-University, Munich, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Doenicke
authors.forename: J
authors.initials: J
authors.lastname: Moss
authors.forename: W
authors.initials: W
authors.lastname: Lorenz
authors.forename: M
authors.initials: M
authors.lastname: Mayer
authors.forename: J
authors.initials: J
authors.lastname: Rau
authors.forename: A
authors.initials: A
authors.lastname: Jedrzejewski
authors.forename: P
authors.initials: P
authors.lastname: Ostwald
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000517:prevention & control; D004115:Dimethindene / Q000627:therapeutic use*; D004311:Double-Blind Method; D003875:Drug Eruptions / Q000209:etiology / Q000517:prevention & control; D005260:Female; D006632:Histamine / Q000097:blood; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006636:Histamine Release / Q000187:drug effects*; D006801:Humans; D007546:Isoquinolines / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D000077590:Mivacurium; D003473:Neuromuscular Nondepolarizing Agents / Q000009:adverse effects*; D011292:Premedication
chemical_list: D006634:Histamine H1 Antagonists; D007546:Isoquinolines; D003473:Neuromuscular Nondepolarizing Agents; D004115:Dimethindene; D000077590:Mivacurium; D006632:Histamine